Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis

Elias J. Jabbour, Koji Sasaki, Farhad Ravandi, Nicholas J. Short, Guillermo Garcia-Manero, Naval Daver, Tapan Kadia, Marina Konopleva, Nitin Jain, Jorge Cortes, Ghayas C. Issa, Jovitta Jacob, Monica Kwari, Philip Thompson, Rebecca Garris, Naveen Pemmaraju, Musa Yilmaz, Susan M. O’Brien, Hagop M. Kantarjian

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Fingerprint

Dive into the research topics of 'Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences